A lawsuit was filed on behalf of investors in Apyx Medical Corporation (NASDAQ: APYX) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 05/14/2019 -- An investor, who purchased shares of Apyx Medical Corporation (NASDAQ: APYX), filed a lawsuit over alleged violations of Federal Securities Laws by Apyx Medical Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Apyx Medical Corporation (NASDAQ: APYX) have certain options and for certain investors are short and strict deadlines running. Deadline: June 17, 2019. NASDAQ: APYX investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
Clearwater, FL based Apyx Medical Corporation f/k/a/ Bovie Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. Apyx Medical Corporation reported that its annual Total Revenue rose from $10.23 million in 2017 to $16.68 million in 2018 and that its Net Loss of $5.06 million in 2017 turned into a Net Income of $64 million in 2018.
On February 21, 2019, White Diamond Research released a report alleging that a clinical study on the use of the Company's J-Plasma for dermal resurfacing may have missed its endpoints.
Then, on April 1, 2019, Apyx Medical Corporation announced that it had withdrawn its 510(k) application for the use of J-Plasma for dermal resurfacing, citing concerns raised by the FDA. Apyx Medical Corporation revealed that the FDA had questioned the device's clinical results, which differed greatly from two of the investigational centers used in the study, as well as the potential impact certain protocol deviations. Moreover, Apyx Medical Corporation disclosed that the clinical study did not meet its primary efficacy endpoint.
The plaintiff claims that between August 1, 2018, and April 1, 2019, the Defendants made false and/or misleading statements and/or failed to disclose that the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint, that, as a result, the clinical study did not support the Company's application for regulatory clearance, that, as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
Those who purchased shares of Apyx Medical Corporation (NASDAQ: APYX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels